Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified March 2026 by AstraZeneca
Sponsor
AstraZeneca
Information Provided by (Responsible Party)
AstraZeneca
Clinicaltrials.gov Identifier
NCT06467357
Other Study ID Numbers:
D781PC00001
First Submitted
May 20, 2024
First Posted
June 20, 2024
Last Update Posted
April 15, 2026
Last Verified
March 2026

ClinicalTrials.gov processed this data on April 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Biliary Tract Cancer
Drug: Trastuzumab deruxtecanDrug: Trastuzumab deruxtecanDrug: Gemcitabine

Study Design

Study TypeInterventional
Actual Enrollment620 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingNone (Open Label)
Primary PurposeTreatment
Official TitleDESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
Study Start DateAugust 11, 2024
Actual Primary Completion Date2yrs 1mo from now
Actual Study Completion Date3yrs 2w from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Trastuzumab deruxtecan + rilvegostomig
Trastuzumab deruxtecan (T-DXd; DS-8201a) in combination with rilvegostomig arm
Drug: Trastuzumab deruxtecan
Experimental therapy by intravenous infusion
Trastuzumab deruxtecan
Trastuzumab deruxtecan (T-DXd; DS-8201a) arm
Drug: Trastuzumab deruxtecan
Experimental therapy by intravenous infusion
Standard of Care
Gemcitabine and cisplatin in combination with durvalumab arm
Drug: Gemcitabine
Standard of care chemotherapy by intravenous infusion

Outcome Measures

Primary Outcome Measures
  1. Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomig
    Safety and tolerability will be evaluated by the proportion of treated patients with occurrence of AEs, SAEs and AESIs, as assessed by CTCAE v5.0.
  2. Randomized Portion: To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care (SoC) in terms of Overall Survival in the FAS (HER2 IHC 3+) population
    Overall survival (OS) in FAS (HER2 IHC 3+) population OS is defined as time from randomization date until the date of death due to any cause. The comparison will include all randomized patients, regardless of whether the patient withdraws from therapy or receives another anticancer therapy. The measure of interest is the hazard ratio of OS.
Secondary Outcome Measures
  1. To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care in terms of Overall Survival in the FAS (HER2 IHC 3+/2+) population
    Overall Survival (OS) in FAS (HER2 IHC 3+/2+) population. OS definition as above.
  2. To evaluate the efficacy of T-DXd monotherapy vs Standard of Care in terms of Overall Survival in the FAS (HER2 IHC 3+) population
    Overall Survival (OS) in FAS (HER2 IHC 3+) population. OS definition as above.
  3. To evaluate the efficacy of T-DXd monotherapy vs Standard of Care in terms of Overall Survival in the FAS (HER2 IHC 3+/2+) population
    Overall Survival (OS) in FAS (HER2 IHC 3+/2+) population. OS definition as above.
  4. To further evaluate efficacy of T-DXd with rilvegostomig vs Standard of Care in terms of Progression Free Survival in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations
    Progression free survival (PFS) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. PFS is defined as time from randomization until progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients, regardless of whether the patient withdraws from randomized therapy, receives another anticancer therapy or clinically progresses prior to RECIST v1.1 progression. The measure of interest is the hazard ratio of PFS.
  5. To further evaluate efficacy of T-DXd monotherapy vs Standard of Care in terms of Progression Free Survival in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations
    Progression free survival (PFS) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. PFS is defined as time from randomization until progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients, regardless of whether the patient withdraws from randomized therapy, receives another anticancer therapy or clinically progresses prior to RECIST v1.1 progression. The measure of interest is the hazard ratio of PFS.
  6. To further evaluate the efficacy of T-DXd with rilvegostomig vs Standrad of Care in terms of objective response rate in the FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations
    Objective response rate (ORR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. ORR is defined as the proportion of patients who achieved CR or PR per RECIST 1.1, as assessed by the investigator. The analysis will include objective response data for all randomized patients from randomization until progression, or up to the last evaluable assessment in the absence of progression. Patients who go off-treatment without a response or progression and then respond while receiving a subsequent therapy will not be included as responders in the ORR calculation. The measure of interest is the risk difference of ORR.
  7. To further evaluate the efficacy of T-DXd monotherapy vs Standrad of Care in terms of objective response rate in the FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations
    Objective response rate (ORR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. ORR is defined as the proportion of patients who achieved CR or PR per RECIST 1.1, as assessed by the investigator. The analysis will include objective response data for all randomized patients from randomization until progression, or up to the last evaluable assessment in the absence of progression. Patients who go off-treatment without a response or progression and then respond while receiving a subsequent therapy will not be included as responders in the ORR calculation. The measure of interest is the risk difference of ORR.
  8. To further evaluate efficacy of T-DXd with rilvegostomig vs Standard if Care in terms of duration of response in patients with HER2-expressing BTC in the FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations
    Duration of response (DoR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. DoR will be defined as the time from the date of first documented response until date of documented progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients who have a response, regardless of whether the patient withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression. The measure of interest is the median DoR.
  9. To further evaluate efficacy of T-DXd monotherapy vs Standard if Care in terms of duration of response in patients with HER2-expressing BTC in the FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations
    Duration of response (DoR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. DoR will be defined as the time from the date of first documented response until date of documented progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients who have a response, regardless of whether the patient withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression. The measure of interest is the median DoR.
  10. To further evaluate the efficacy of T-DXd with rilvegostomig versus T-DXd monotherapy in terms of Overall survival in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations.
    Overall survival (OS) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. OS is defined as time from randomization date until the date of death due to any cause. The comparison will include all randomized patients, regardless of whether the patient withdraws from therapy or receives another anticancer therapy. The measure of interest is the hazard ratio of OS.
  11. To further evaluate the efficacy of T-DXd with rilvegostomig versus T-DXd monotherapy in terms of PFS in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations
    Progression free survival (PFS) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. PFS is defined as time from randomization until progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients, regardless of whether the patient withdraws from randomized therapy, receives another anticancer therapy or clinically progresses prior to RECIST v1.1 progression. The measure of interest is the hazard ratio of PFS.
  12. To further evaluate the efficacy of T-DXd with rilvegostomig versus T-DXd monotherapy in terms of Duration of response in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations
    Duration of response (DoR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. DoR will be defined as the time from the date of first documented response until date of documented progression per RECIST v1.1, or death due to any cause. The analysis will include all randomized patients who have a response, regardless of whether the patient withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression. The measure of interest is the median DoR.
  13. To further evaluate the efficacy of T-DXd with rilvegostomig versus T-DXd monotherapy in terms of Objective response rate in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations
    Objective response rate (ORR) in FAS (HER2 IHC 3+) and FAS (HER2 IHC 3+/2+) populations. ORR is defined as the proportion of patients who achieved CR or PR per RECIST 1.1, as assessed by the investigator. The analysis will include objective response data for all randomized patients from randomization until progression, or up to the last evaluable assessment in the absence of progression. Patients who go off-treatment without a response or progression and then respond while receiving a subsequent therapy will not be included as responders in the ORR calculation. The measure of interest is the risk difference of ORR.
  14. To assess the safety and tolerability of T-DXd with rilvegostomig vs Standard of Care
    Safety and tolerability will be evaluated by the proportion of treated patients with occurrence of AEs, SAEs and AESIs, as assessed by CTCAE v5.0.
  15. To assess the safety and tolerability of T-DXd monotherapy vs Standard of Care
    Safety and tolerability will be evaluated by the proportion of treated patients with occurrence of AEs, SAEs and AESIs, as assessed by CTCAE v5.0.
  16. To describe patient-reported tolerability of T-DXd with rilvegostomig in comparison to Standard of Care based on a summary of symptomatic AEs
    Patient-reported tolerability will be described using the Symptomatic adverse events: Descriptive summary of the proportion of patients reporting symptomatic AEs while on treatment using items from the EORTC Item Library (on EORTC IL form 322).
  17. To describe patient-reported tolerability of T-DXd monotherapy in comparison to SoC based on a summary of symptomatic AEs
    Patient-reported tolerability will be described using the Symptomatic adverse events: Descriptive summary of the proportion of patients reporting symptomatic AEs while on treatment using items from the EORTC Item Library (on EORTC IL form 322)
  18. To describe patient-reported tolerability of T-DXd with rilvegostomig in comparison to T-DXd monotherapy based on a summary of symptomatic AEs
    Patient-reported tolerability will be described using the Symptomatic adverse events: Descriptive summary of the proportion of patients reporting symptomatic AEs while on treatment using items from the EORTC Item Library (on EORTC IL form 322).
  19. To assess time to deterioration in physical functioning in patients treated with T-DXd with rilvegostomig vs Standard of Care
    Time to deterioration (TTD) in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c - TTD is defined as time from the date of randomization to the date of deterioration. Deterioration is defined as the change from baseline that reaches a clinically meaningful deterioration threshold. \- The measure of interest is the HR of TTD in physical function. The analysis will include all randomized patients as randomized.
  20. To assess time to deterioration in physical functioning in patients treated with T-DXd monotherapy vs Standard of care
    Time to deterioration (TTD) in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c - TTD is defined as time from the date of randomization to the date of deterioration. Deterioration is defined as the change from baseline that reaches a clinically meaningful deterioration threshold. \- The measure of interest is the HR of TTD in physical function. The analysis will include all randomized patients as randomized.
  21. To assess time to deterioration in physical functioning in patients treated with T-DXd with rilvegostomig vs T-DXd monotherapy
    Time to deterioration (TTD) in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c - TTD is defined as time from the date of randomization to the date of deterioration. Deterioration is defined as the change from baseline that reaches a clinically meaningful deterioration threshold. \- The measure of interest is the HR of TTD in physical function. The analysis will include all randomized patients as randomized.
  22. To assess the pharmacokinetics of T-DXd, total anti- HER2 antibody, DXd and rilvegostomig in serum
    Descriptive analysis of serum concentration of T-DXd, total anti-HER2 antibody, DXd and rilvegostomig in all applicable arms.
  23. To investigate the immunogenicity of T-DXd and of rilvegostomig
    Descriptive summary of presence of ADAs for T-DXd and rilvegostomig in all applicable arms.
  24. To describe patient-reported tolerability of T-DXd with rilvegostomig in comparison to Standard of Care based on overall side-effect bother
    Patient-reported tolerability will be described using the Overall side-effect bother that will be mesured using PGI-TT
  25. To describe patient-reported tolerability of T-DXd monotherapy in comparison to SoC based on overall side-effect bother
    Patient-reported tolerability will be described using the Overall side-effect bother that will be assessed will be mesured using PGI-TT
  26. To assess the safety and tolerability of T-DXd with rilvegostomig vs T-DXd monotherapy
    Safety and tolerability will be evaluated by the proportion of treated patients with occurrence of AEs, SAEs and AESIs, as assessed by CTCAE v5.0.
  27. To describe patient-reported tolerability of T-DXd with rilvegostmog in comparison to T-DXd monotherapy based on overall side-effect bother
    Patient-reported tolerability will be described using the Overall side-effect bother that will be assessed will be mesured using PGI-TT.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Male and female patients must be at least 18 years of age at the time of signing the informed consent. Other age restrictions may apply as per local regulations.
Unresectable, previously untreated, locally advanced or metastatic biliary tract adenocarcinoma. Prior treatment in the perioperative and/or adjuvant setting is permissible provided there is \> 3 months (90 days) between the end of adjuvant treatment and the diagnosis of locally advanced or metastatic disease.
Histologically confirmed HER2-expressing (IHC 3+ or IHC 2+) BTC.
Patients must provide an FFPE tumor sample that is no older than 3 years for tissue-based IHC staining to centrally determine HER2 expression, PD-L1 status, and other correlatives.
Has at least one target lesion assessed by the Investigator based on RECIST v1.1. (Randomized portion only)
WHO/ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
Adequate organ and bone marrow function within 14 days before randomization.
Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential.
Minimum life expectancy of 12 weeks. Key
Exclusion Criteria
Prior exposure to other HER2 targeting therapies, ADCs, immune checkpoint inhibitors and therapeutic anticancer vaccines.
Histologically confirmed ampullary carcinoma.
Any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the Investigator, interfere with the patient's participation in the clinical study or evaluation of the clinical study results.
Spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
Medical history of myocardial infarction within 6 months before randomization/enrollment, symptomatic congestive heart failure (New York Heart Association Class II to IV), unstable angina pectoris, clinically important cardiac arrhythmias, or a recent (\< 6 months) cardiovascular event including stroke.
Serious chronic gastrointestinal conditions associated with diarrhea (eg, active inflammatory bowel disease); active non-infectious skin disease (including any grade rash, urticaria, dermatitis, ulceration, or psoriasis) requiring systemic treatment.
Active autoimmune, connective tissue or inflammatory disorders that has required systemic treatment in the past 2 years, or where there is documented, or a suspicion of pulmonary involvement at the time of screening.
Corrected QT interval (QTcF) prolongation to \> 470 msec (females) or \> 450 msec (males) based on average of the screening triplicate 12-lead ECG.
History of (non-infectious) ILD/pneumonitis, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (eg, pulmonary emboli within three months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion etc).
Prior pneumonectomy (complete).
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. Patients with prior cholangitis/biliary tract infections/biliary intervention (eg, stent, external drain) should have completed a full course of antibiotics prior to randomization.
Active primary immunodeficiency, known uncontrolled active HIV infection or HCV.
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected nonmelanoma skin cancer and curatively treated in situ disease. For certain participant populations, exceptions could also include carcinomas in-situ or Ta tumors treated with curative intent.
Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (Drainage and Cell free and Concentrated Ascites Reinfusion Therapy are not allowed within 2 weeks prior to screening assessment).
Any concurrent anticancer treatment without an adequate washout period prior to randomization. Concurrent use of hormonal therapy for non-cancer related conditions (eg, hormone replacement therapy) is allowed.
History of organ transplants or allogenic stem cell transplant.

Contacts and Locations

Sponsors and CollaboratorsAstraZeneca
Locations
Research Site | Scottsdale Arizona, United States, 85259Research Site | Tucson Arizona, United States, 85704Research Site | Tucson Arizona, United States, 85719Research Site | Fullerton California, United States, 92835Research Site | La Jolla California, United States, 92093Research Site | Los Alamitos California, United States, 90720Research Site | Los Angeles California, United States, 90017Research Site | Los Angeles California, United States, 90089Research Site | San Francisco California, United States, 94143Research Site | Walnut Creek California, United States, 94598Research Site | Washington D.C. District of Columbia, United States, 20007Research Site | Fort Myers Florida, United States, 33901Research Site | Jacksonville Florida, United States, 32224Research Site | St. Petersburg Florida, United States, 33705Research Site | Tampa Florida, United States, 33606Research Site | West Palm Beach Florida, United States, 33401Research Site | Atlanta Georgia, United States, 30309Research Site | Coeur d'Alene Idaho, United States, 83814Research Site | Chicago Illinois, United States, 60612Research Site | Niles Illinois, United States, 60714Research Site | Towson Maryland, United States, 21204Research Site | Worcester Massachusetts, United States, 01655Research Site | Detroit Michigan, United States, 48202Research Site | Grand Rapids Michigan, United States, 49503Research Site | Rochester Minnesota, United States, 55905Research Site | Kansas City Missouri, United States, 64132Research Site | St Louis Missouri, United States, 63110Research Site | Albuquerque New Mexico, United States, 87102Research Site | New York New York, United States, 10032Research Site | White Plains New York, United States, 10601Research Site | Cleveland Ohio, United States, 44111Research Site | Cleveland Ohio, United States, 44124Research Site | Cleveland Ohio, United States, 44195Research Site | Columbus Ohio, United States, 43210Research Site | Pittsburgh Pennsylvania, United States, 15232Research Site | Greenville South Carolina, United States, 29605Research Site | Nashville Tennessee, United States, 37203Research Site | Austin Texas, United States, 78705Research Site | Dallas Texas, United States, 75246Research Site | Fort Worth Texas, United States, 76104Research Site | Fort Worth Texas, United States, 76104Research Site | Houston Texas, United States, 77030Research Site | Pearland Texas, United States, 77584Research Site | San Antonio Texas, United States, 78217Research Site | San Antonio Texas, United States, 78258Research Site | Fairfax Virginia, United States, 22031Research Site | Chermside , Australia, 4032Research Site | Clayton , Australia, 3168Research Site | Concord , Australia, 2139Research Site | Nedlands , Australia, 6009Research Site | Graz , Austria, 8036Research Site | Linz , Austria, 4010Research Site | Salzburg , Austria, 5020Research Site | Vienna , Austria, 1090Research Site | Wiener Neustadt , Austria, 2700Research Site | Anderlecht , Belgium, 1070Research Site | Edegem , Belgium, 2650Research Site | Ghent , Belgium, 9000Research Site | Leuven , Belgium, 3000Research Site | Liège , Belgium, 4000Research Site | Roeselare , Belgium, 8800Research Site | Natal , Brazil, 59012-300Research Site | Porto Alegre , Brazil, 90035-000Research Site | Porto Alegre , Brazil, 91350-200Research Site | Santa Maria , Brazil, 97015-450Research Site | São Paulo , Brazil, 01246-000Research Site | São Paulo , Brazil, 05651-901Research Site | Vitória , Brazil, 29043-272Research Site | Edmonton Alberta, Canada, T6G 1Z2Research Site | Halifax Nova Scotia, Canada, B3H 1V7Research Site | Brampton Ontario, Canada, L6R 3J7Research Site | Toronto Ontario, Canada, M5G 2M9Research Site | Montreal Quebec, Canada, H3A 1A1Research Site | Beijing , China, 100020Research Site | Beijing , China, 100021Research Site | Beijing , China, 100034Research Site | Beijing , China, 100142Research Site | Beijing , China, Research Site | Bengbu , China, 233004Research Site | Changchun , China, 130021Research Site | Changde , China, 415000Research Site | Changsha , China, 410013Research Site | Chengdu , China, 610041Research Site | Chengdu , China, 610078Research Site | Chongqing , China, 400030Research Site | Fuzhou , China, 350007Research Site | Guangzhou , China, 510080Research Site | Guangzhou , China, 510515Research Site | Guiyang , China, 550044Research Site | Hangzhou , China, 310016Research Site | Harbin , China, 150081Research Site | Hefei , China, 230001Research Site | Hefei , China, 230601Research Site | Jinan , China, 250117Research Site | Kunming , China, 650101Research Site | Linyi , China, 276000Research Site | Luoyang , China, 471000Research Site | Nanchang , China, 330029Research Site | Nanjing , China, 2100008Research Site | Nanning , China, 530021Research Site | Nantong , China, 226001Research Site | Shanghai , China, 200001Research Site | Shanghai , China, 201107Research Site | Shanghai , China, 201114Research Site | Shenyang , China, 110004Research Site | Shenzhen , China, 518116Research Site | Tianjin , China, 300060Research Site | Weifang , China, 261000Research Site | Wenzhou , China, 325035Research Site | Wuhan , China, 430079Research Site | Xi'an , China, 710061Research Site | Zhengzhou , China, 450008Research Site | Zhengzhou , China, 450052Research Site | Brno , Czechia, 625 00Research Site | Brno , Czechia, 656 53Research Site | Hradec Králové , Czechia, 500 05Research Site | Olomouc , Czechia, 77900Research Site | Prague , Czechia, 100 34Research Site | Prague , Czechia, 15006Research Site | Brest , France, 29609Research Site | Clichy , France, 92118Research Site | Dijon , France, 21079Research Site | Lille , France, 59037Research Site | Lyon , France, 69008Research Site | Lyon , France, 69373Research Site | Marseille , France, 13008Research Site | Montpellier , France, 34295Research Site | Pessac , France, 33604Research Site | Villejuif , France, 94800Research Site | Berlin , Germany, 13353Research Site | Bonn , Germany, 53127Research Site | Cologne , Germany, 50937Research Site | Dresden , Germany, 01370Research Site | Frankfurt , Germany, 60488Research Site | Freiburg im Breisgau , Germany, 79106Research Site | Göttingen , Germany, 37075Research Site | Hamburg , Germany, 22763Research Site | Leipzig , Germany, 4103Research Site | Lübeck , Germany, 23538Research Site | München , Germany, 81377, DEResearch Site | Ulm , Germany, 89081Research Site | Würzburg , Germany, 97080Research Site | Hong Kong , Hong Kong, 999077Research Site | Shatin , Hong Kong, 00000Research Site | Dehradun , India, 248016Research Site | Delhi , India, 110029Research Site | Delhi , India, 110088Research Site | Kanpur , India, 208001Research Site | Kolkata , India, 700054Research Site | Kolkata , India, 700094Research Site | Mumbai , India, 400012Research Site | Vadodara , India, 391760Research Site | Varanasi , India, 221005Research Site | Florence , Italy, 50134Research Site | Milan , Italy, 20132Research Site | Milan , Italy, 20162Research Site | Naples , Italy, 80128Research Site | Naples , Italy, 80131Research Site | Padova , Italy, 35128Research Site | Roma , Italy, 00133Research Site | Rozzano , Italy, 20089Research Site | Tricase , Italy, 73039Research Site | Bunkyō City , Japan, 113-8431Research Site | Bunkyō City , Japan, 113-8603Research Site | Bunkyō City , Japan, 113-8677Research Site | Chiba , Japan, 260-0877Research Site | Fukuyama-shi , Japan, 721-8511Research Site | Hirakata-shi , Japan, 573-1191Research Site | Hiroshima , Japan, 734-8551Research Site | Kanazawa , Japan, 920-8641Research Site | Kashiwa , Japan, 227-8577Research Site | Kawasaki-shi , Japan, 216-8511Research Site | Kita-gun , Japan, 761-0793Research Site | Kitaadachi-gun , Japan, 362-0806Research Site | Kōtoku , Japan, 135-8550Research Site | Kumamoto , Japan, 860-8556Research Site | Kyoto , Japan, 606-8507Research Site | Maebashi , Japan, 371-8511Research Site | Mitaka-shi , Japan, 181-8611Research Site | Nagoya , Japan, 464-8681Research Site | Nagoya , Japan, 466-8560Research Site | Osaka , Japan, 541-8567Research Site | Osaka , Japan, 545-8586Research Site | Sakaishi , Japan, 591-8025Research Site | Sapporo , Japan, 060-8543Research Site | Sendai , Japan, 980-8574Research Site | Shinjuku-ku , Japan, 160-8582Research Site | Suita , Japan, 565-0871Research Site | Sunto-gun , Japan, 411-8777Research Site | Ube-shi , Japan, 755-8505Research Site | Wakayama , Japan, 641-8510Research Site | Yokohama , Japan, 241-8515Research Site | George Town , Malaysia, 10990Research Site | Johor Bahru , Malaysia, 81100Research Site | Kuala Lumpur , Malaysia, 50586Research Site | Kuala Lumpur , Malaysia, 59100Research Site | Kuching , Malaysia, 93586Research Site | Rotterdam , Netherlands, 3015 GDResearch Site | Cebu City , Philippines, 6000Research Site | Makati , Philippines, 1229Research Site | Pasig , Philippines, 1605Research Site | Quezon City , Philippines, 1112Research Site | Bialystok , Poland, 15-027Research Site | Katowice , Poland, 40-514Research Site | Krakow , Poland, 31-501Research Site | Lublin , Poland, 20-080Research Site | Warsaw , Poland, 02-034Research Site | Wroclaw , Poland, 50-556Research Site | Dammam , Saudi Arabia, 31444Research Site | Riyadh , Saudi Arabia, 11426Research Site | Riyadh , Saudi Arabia, 11525Research Site | Riyadh , Saudi Arabia, 12713Research Site | Banská Bystrica , Slovakia, 974 01Research Site | Bratislava , Slovakia, 833 10Research Site | Košice , Slovakia, 041 91Research Site | Martin , Slovakia, 036 59Research Site | Trnava , Slovakia, 917 75Research Site | Busan , South Korea, 48108Research Site | Gyeonggi-do , South Korea, 13620Research Site | Hwasun-gun , South Korea, 58128Research Site | Seongnam-si , South Korea, 13496Research Site | Seoul , South Korea, 03080Research Site | Seoul , South Korea, 05505Research Site | Seoul , South Korea, 06351Research Site | Seoul , South Korea, 06591Research Site | Seoul , South Korea, 120-752Research Site | Barcelona , Spain, 08035Research Site | Madrid , Spain, 28007Research Site | Madrid , Spain, 28040Research Site | Madrid , Spain, 28041Research Site | Málaga , Spain, 29010Research Site | Santander , Spain, 39008Research Site | Kaohsiung City , Taiwan, 00807Research Site | Kaohsiung City , Taiwan, 82445Research Site | Kaohsiung City , Taiwan, 833Research Site | Taichung , Taiwan, 40447Research Site | Taichung , Taiwan, 407219Research Site | Taipei , Taiwan, 10002Research Site | Taipei , Taiwan, Research Site | Taoyuan District , Taiwan, 333Research Site | Bangkok , Thailand, 10400Research Site | Hat Yai , Thailand, 90110Research Site | Khon Kaen , Thailand, 40002Research Site | Muang , Thailand, 50200Research Site | Mueang , Thailand, 47000Research Site | Naimuang , Thailand, 30000Research Site | Ongkharak , Thailand, 26120Research Site | Si Sa Ket , Thailand, 33000Research Site | Altındağ , Turkey (Türkiye), 06230Research Site | Antalya , Turkey (Türkiye), 07100Research Site | Istanbul , Turkey (Türkiye), 34218Research Site | Izmir , Turkey (Türkiye), 35340Research Site | Mezitli , Turkey (Türkiye), 33200Research Site | Yakutiye , Turkey (Türkiye), 25040Research Site | Birmingham , United Kingdom, B15 2GWResearch Site | Dundee , United Kingdom, DD1 9SYResearch Site | Glasgow , United Kingdom, G12 0YNResearch Site | Greater London , United Kingdom, SW3 6JJResearch Site | Leeds , United Kingdom, LS9 7TFResearch Site | London , United Kingdom, EC1A 7BEResearch Site | Hanoi , Vietnam, 100000Research Site | Ho Chi Minh City , Vietnam, 700000Research Site | Ho Chi Minh City , Vietnam, 700000Research Site | Ho Chi Minh City , Vietnam, 70000Research Site | Ho Chi Minh City , Vietnam, 70000Research Site | Vinh , Vietnam, 460000